Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.

This study showed evidence that BRV may be an effective adjunctive therapy in patients with drug-resistant focal or generalized epilepsies whose seizures have previously not responded or tolerated LEV therapy. We demonstrated a higher incidence of treatment-emergent AEs leading to lower retention rates compared with previous studies across all patient groups. There were, however, no significant differences in tolerability between patients with preexisting psychiatric or behavioral comorbidities, or intellectual disability to those without. PMID: 31493736 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31493736?dopt=Abstract

Source: Epilepsy and Behaviour - September 3, 2019 Category: Neurology Authors: Foo EC, Geldard J, Peacey C, Wright E, Eltayeb K, Maguire M Tags: Epilepsy Behav Source Type: research